Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292553 | 0.83 | PARP1 (0.74) | PARP1PARP2 | |
| SCHEMBL2297309 | 0.80 | PARP1 (0.56) | PARP1PARP2 | |
| SCHEMBL6964340 | 0.77 | PARP1 (0.53) | PARP1PARP2 | |
| SCHEMBL5621570 | 0.75 | PARP1 (0.81) | PARP1PARP2 | |
| SCHEMBL631318 | 0.74 | PARP1 (0.70) | PARP1PARP2 | |
| SCHEMBL7200439 | 0.74 | AURKA (0.57) | PARP1 | |
| SCHEMBL25022851 | 0.74 | PARP1 (0.63) | PARP1PARP2 | |
| SCHEMBL3635473 | 0.73 | AURKB (0.75) | PARP1PARP2 | |
| SCHEMBL23581692 | 0.73 | PARP1 (0.66) | PARP1 | |
| SCHEMBL6841122 | 0.73 | PARP1 (0.61) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | AGOURON PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003106430-A1 | BENZIMIDAZOLE INHIBITORS OF POLY(ADP-RIBOSYL) POLYMERASE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.